PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 03, 2022 at 11:49 pm
Share
PharmaEngine, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 166.9 million compared to TWD 158.26 million a year ago. Net income was TWD 80.67 million compared to TWD 165.66 million a year ago. Basic earnings per share from continuing operations was TWD 0.56 compared to TWD 1.14 a year ago. Diluted earnings per share from continuing operations was TWD 0.56 compared to TWD 1.14 a year ago.
For the six months, sales was TWD 341.03 million compared to TWD 273.91 million a year ago. Net income was TWD 177.7 million compared to TWD 241.35 million a year ago. Basic earnings per share from continuing operations was TWD 1.24 compared to TWD 1.66 a year ago. Diluted earnings per share from continuing operations was TWD 1.24 compared to TWD 1.66 a year ago.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,